Herpes Zoster Vaccine in Older Adults and the Risk of Subsequent Herpes Zoster Disease

Tseng, Hung Fu; Smith, Ning; Harpaz, Rafael; Bialek, Stephanie R.; Sy, Lina S.; Jacobsen, Steven J.

doi:10.1001/jama.2010.1983

Cited by 212 publications

(157 citation statements)

References 33 publications

Supporting

Mentioning

142

Contrasting

Unclassified

Order By: Relevance

“…Studies revealed that 2 doses of HZ/su containing 50 μg of recombinant VZV glycoprotein E administered at 1-or 2-month intervals were well-tolerated and induced much more robust VZV-specific and VZV glycoprotein E-specific CD4 + T cell and antibody responses than did vOka (55,56). A randomized placebo-controlled study of 15,411 subjects ≥ 50 years of age revealed a remarkable 97.2% efficacy in preventing zoster for a 3.2-year period that did not diminish with increasing age (57).…”

Section: Gsk Vaccine (Hz/su)mentioning

confidence: 99%

Varicella Zoster Virus: A Common Cause of Stroke in Children and Adults

Amlie‐Lefond

Gilden

2016

Journal of Stroke and Cerebrovascular Diseases

104

View full text Add to dashboard Cite

Background-Varicella zoster virus (VZV) is a neurotropic exclusively human herpesvirus. Primary infection causes varicella (chickenpox), after which virus become latent in ganglionic neurons along the entire neuraxis. As cell-mediated immunity to VZV declines with advancing age and immunosuppression, VZV reactivates to produce zoster (shingles). One of the most serious complications of zoster is VZV vasculopathy.

show abstract

Section: Gsk Vaccine (Hz/su)mentioning

confidence: 99%

Varicella Zoster Virus: A Common Cause of Stroke in Children and Adults

Amlie‐Lefond

Gilden

2016

Journal of Stroke and Cerebrovascular Diseases

104

View full text Add to dashboard Cite

show abstract

“…14 To date, only 2 estimates of HZ vaccine effectiveness have been published. 15,16 Both studies used electronic-billing data without medical record confirmation which can result in misclassification of both exposure (vaccination status) and outcome (occurrence of HZ). 1,17 Furthermore, neither provided clinical information on HZ characteristics among vaccinated persons, precluding a complete description of the vaccine's impact.…”

Section: Introductionmentioning

confidence: 99%

Herpes zoster vaccine effectiveness and manifestations of herpes zoster and associated pain by vaccination status

Marin

Yawn

Hales

et al. 2015

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Options for managing herpes zoster (HZ)-related pain and complications have limited effectiveness, making HZ prevention through vaccination an important strategy. Limited data are available on HZ vaccine effectiveness against confirmed HZ and manifestations of HZ among vaccinated persons. We conducted a matched case-control study to assess HZ vaccine effectiveness for prevention of HZ and other HZ-related outcomes and a cohort study of persons with HZ to compare HZ-related outcomes by vaccination status. Cases were identified through active surveillance among persons age 60 years with HZ onset and health-care encounters during 2010-2011 in Southeastern Minnesota. Controls were age-and sex-matched to cases. Data were collected by medical record review and from participants via interviews and daily pain diaries. 266 HZ case-patients and 362 matched controls were enrolled in the vaccine effectiveness studies and 303 case-patients in the cohort study of HZ characteristics by vaccination status. Vaccination was associated with 54% (95% CI:32%-69%) reduction in HZ incidence, 58% (95% CI:31%-75%) reduction in HZ prodromal symptoms, and 70% (95% CI:33%-87%) reduction in medically-attended prodrome. HZ vaccine was statistically significant effective at preventing postherpetic neuralgia (PHN) measured at 30 d after rash onset, 61% (95% CI: 22%-80%). Among persons who developed HZ, no differences were found by vaccination status in severity or duration of HZ pain after rash onset. In this population-based study, HZ vaccination was associated with >50% reduction in HZ, HZ prodrome, and medically-attended prodrome.

show abstract

“…A cohort study, using routinely collected claims data from the Kaiser Permanente health plan in the USA, identified 75,761 vaccinated individuals over 60 years and matched each to three unvaccinated controls; the incidence of zoster was reduced by 55% in those vaccinated [85]. Unpublished data from the Clinical Practice Research Datalink, a routinely collected primary care database of almost 13 million patients in the UK, suggests that among patients in England aged between 65 and 84 years, there has been a 22% decline in consultations for zoster among those eligible for vaccination, compared to those ineligible [66].…”

Section: Development Of a Vaccine Against Zoster Efficacy And Safetymentioning

confidence: 99%

Varicella and herpes zoster vaccine development: lessons learned

Warren‐Gash

Forbes

Breuer

2017

Expert Review of Vaccines

View full text Add to dashboard Cite

Introduction: Before vaccination, varicella zoster virus (VZV), which is endemic worldwide, led to almost universal infection. This neurotropic virus persists lifelong by establishing latency in sensory ganglia, where its reactivation is controlled by VZV-specific T-cell immunity. Lifetime risk of VZV reactivation (zoster) is around 30%. Vaccine development was galvanised by the economic and societal burden of VZV, including debilitating zoster complications that largely affect older individuals. Areas covered: We describe the story of development, licensing and implementation of live attenuated vaccines against varicella and zoster. We consider the complex backdrop of VZV virology, pathogenesis and immune responses in the absence of suitable animal models and examine the changing epidemiology of VZV disease. We review the vaccines’ efficacy, safety, effectiveness and coverage using evidence from trials, observational studies from large routine health datasets and clinical post-marketing surveillance studies and outline newer developments in subunit and inactivated vaccines. Expert commentary: Safe and effective, varicella and zoster vaccines have already made major inroads into reducing the burden of VZV disease globally. As these live vaccines have the potential to reactivate and cause clinical disease, developing alternatives that do not establish latency is an attractive prospect but will require better understanding of latency mechanisms.

show abstract

Herpes Zoster Vaccine in Older Adults and the Risk of Subsequent Herpes Zoster Disease

Cited by 212 publications

References 33 publications

Varicella Zoster Virus: A Common Cause of Stroke in Children and Adults

Varicella Zoster Virus: A Common Cause of Stroke in Children and Adults

Herpes zoster vaccine effectiveness and manifestations of herpes zoster and associated pain by vaccination status

Varicella and herpes zoster vaccine development: lessons learned

Contact Info

Product

Resources

About